Moulay Alaoui-Jamali completed his training in cancer Pharmacology and Molecular Oncology at the French National Cancer Institute in Paris, at the Faculty of Medicine of the Université Paris-Sud, as well as the Roswell Park Cancer Institute in the United States. His research focuses on the biology of the progression of primary breast cancer to metastasis, anti-cancer drugs pharmacology and the discovery of new therapeutic targets.
Why Choosing Breast Cancer?
Breast cancer is among the most complex diseases due to its biology, its heterogeneity, its risk factors and other aspects. Although our knowledge about this disease and its treatment modalities have steadily improved, several questions concerning the mechanisms of its progression and recurrence after treatment still remain unanswered. With this in mind, Dr. Alaoui-Jamali became interested in this disease because of the challenge involved in demystifying its complex biology and because there is an enormous potential to discover more effective innovative therapies which can benefit not only breast cancer patients, but also patients affected by other types of cancers with similar mechanistic aspects.
A Scientific Accomplishment You Are Proud of
One of our accomplishments which represents a significant contribution in this area is our discovery showing the role of signalling through pathways of focal adhesion in the progression of primary breast cancer to metastasis. This discovery made it possible to find new therapeutic approaches targeting this signalling pathway and resulting in the reprogramming of metastatic cancer cells to indolent cells. This approach has an enormous clinical potential to improve treatment of advanced or recurring breast cancer.
- Cancer biology
- Discovery of new therapeutic targets
- Development of scientific models
Projects Funded by the Foundation
2008 – Focal adhesion regulators of early invasive breast cancer: Therapeutic targeting in preclinical models and clinical validation in progressive breast cancer
2011 – Optimization of novel therapeutic approach targeting breast cancer cell plasticity and epithelial-to-mesenchymal transition for metastatic breast cancer
2014 – Preclinical studies of anti-metastatic molecules capable to reprogram invasive breast cancer cells expressing EMT/stem cell markers